We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Baebies

Baebies develops and commercializes products and services that enable early disease detection and comprehensive diagn... read more Featured Products: More products

Download Mobile App




First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

By LabMedica International staff writers
Posted on 08 May 2025

Heparin dosing requires careful management to avoid both bleeding and clotting complications. More...

In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%, with bleeding occurring in over one-third of patients. Anti-Factor Xa tests, the preferred method for monitoring heparin therapy, are typically conducted in central labs and take over an hour to return results, leading to delays in crucial dosing decisions. Now, a new point-of-care heparin monitoring assay designed for patients receiving unfractionated or low molecular weight heparin offers results in under 15 minutes from just 50 µL of whole blood.

Baebies (Durham, NC, USA) has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Anti-Factor Xa test on the FINDER platform. This designation highlights the test’s potential to bring heparin monitoring directly to the patient, enabling faster and more efficient dose management in critical care settings. Unlike existing tests, the FINDER Anti-Factor Xa Test requires no centrifugation and can be performed directly at the point of care or in a central lab, providing results within minutes. The test addresses a life-threatening condition, offers substantial improvements over current methods, introduces breakthrough technology where no approved alternatives exist, and aligns with the FDA’s Breakthrough Device criteria, ultimately benefiting patients.

"This designation provides priority FDA review and dedicated regulatory guidance, accelerating our efforts to bring the test to market," said Richard West, Founder and CEO of Baebies. "It positions FINDER to expand rapidly into the multi-billion-dollar coagulation testing space."


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Collection and Transport System
PurSafe Plus®
Pipette
Accumax Smart Series
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.